Rociletinib in EGFR-mutated non-small-cell lung cancer.

doi:10.1056/NEJMoa1413654

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Rociletinib in EGFR-mutated non-small-cell lung cancer.

The New England journal of medicine - 30 Apr 2015

Sequist Lecia V, Soria Jean-Charles, Goldman Jonathan W, Wakelee Heather A, Gadgeel Shirish M, Varga Andrea, Papadimitrakopoulou Vassiliki, Solomon Benjamin J, Oxnard Geoffrey R, Dziadziuszko Rafal, Aisner Dara L, Doebele Robert C, Galasso Cathy, Garon Edward B, Heist Rebecca S, Logan Jennifer, Neal Joel W, Mendenhall Melody A, Nichols Suzanne, Piotrowska Zofia, Wozniak Antoinette J, Raponi Mitch, Karlovich Chris A, Jaw-Tsai Sarah, Isaacson Jeffrey, Despain Darrin, Matheny Shannon L, Rolfe Lindsey, Allen Andrew R, Camidge D Ross

Abstract excerpt

BACKGROUND: Non-small-cell lung cancer (NSCLC) with a mutation in the gene encoding epidermal growth factor receptor (EGFR) is sensitive to approved EGFR inhibitors, but resistance develops, mediated by the T790M EGFR mutation in most cases. Rociletinib (CO-1686) is an EGFR inhibitor active in preclinical models of EGFR-mutated NSCLC with or without T790M. METHODS: In this phase 1-2 study, we administered...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Dose-Response Relationship, Drug

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Hyperglycemia

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Open in PubMed

Identifiers

PMID: 25923550
DOI: 10.1056/NEJMoa1413654

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rociletinib in EGFR-mutated non-small-cell lung cancer.PMID 25923550Read ↗

Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung CancerSemantic proximity Read ↗

Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions.Semantic proximity Read ↗

Rociletinib for EGFR-mutated Non–Small-Cell Lung CancerSemantic proximity Read ↗

Safety, pharmacokinetics, and efficacy of BPI-15086 in patients with EGFR T790M-mutated advanced non-small-cell lung cancer: results from a phase I, single-arm, multicenter study.Semantic proximity Read ↗

The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic.Semantic proximity Read ↗

Novel Selective and Potent EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non-small cell lung cancer.Semantic proximity Read ↗

Synthesis and Fundamental Evaluation of Radioiodinated Rociletinib (CO-1686) as a Probe to Lung Cancer with L858R/T790M Mutations of Epidermal Growth Factor Receptor (EGFR).Semantic proximity Read ↗

3009 Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvementSemantic proximity Read ↗

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.Semantic proximity Read ↗

Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.